If a person stops treatment with Wegovy, they may experience the following cardiovascular symptoms: increased blood pressure increased cholesterol levels irregular heartbeat nausea and vomiting headaches chest pain dizziness difficulty breathing nosebleeds buzzing in the ears vision changes confusion anxiety In the same study, prediabetes returned in some people who used Wegovy for 68 weeks and then stopped treatment
Substantial weight loss usually becomes apparent after 8 to 12 weeks of consistent use
As their use expands globally, it becomes increasingly important to evaluate all components of these therapies, not just the active compound." Story Source: Materials provided by Adelaide University
The current studies indicate that, not only is somatostatin likely to profoundly regulate secretion of the alpha and beta cells, but somatostatin secretion is itself regulated by glucagon secretion
Acknowledgement The patient in this manuscript has given written informed consent to the publication of his case details and photographs
Like other GLP-1 medications, weight regain is expected if treatment is discontinued
